I thought I heard 80 something cents but maybe not.  DM mentions (31:00) that the latest financing occured the day prior (Oct 26) and it was less than a buck (that would be US $).  I can't get the doc to display on Sedar.

If the talazoparib (Pfizer) Phase II ORR passes the 30% mark, as DM discussed (16:00), that might jump start negotiations with Pfizer (or another pharma).

Otherwise I expect to wait at least 2-3 years for a deal or buyout -- until a pharma sees near-term revenue.